Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

C4 Therapeutics (CCCC) Invested Capital (2019 - 2025)

Historic Invested Capital for C4 Therapeutics (CCCC) over the last 7 years, with Q3 2025 value amounting to $154.4 million.

  • C4 Therapeutics' Invested Capital fell 3636.75% to $154.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $154.4 million, marking a year-over-year decrease of 3636.75%. This contributed to the annual value of $216.0 million for FY2024, which is 1224.15% down from last year.
  • As of Q3 2025, C4 Therapeutics' Invested Capital stood at $154.4 million, which was down 3636.75% from $174.1 million recorded in Q2 2025.
  • Over the past 5 years, C4 Therapeutics' Invested Capital peaked at $416.4 million during Q2 2021, and registered a low of $154.4 million during Q3 2025.
  • For the 5-year period, C4 Therapeutics' Invested Capital averaged around $278.3 million, with its median value being $258.3 million (2024).
  • In the last 5 years, C4 Therapeutics' Invested Capital soared by 40831.6% in 2021 and then plummeted by 3636.75% in 2025.
  • Quarter analysis of 5 years shows C4 Therapeutics' Invested Capital stood at $389.6 million in 2021, then decreased by 22.82% to $300.7 million in 2022, then dropped by 18.16% to $246.1 million in 2023, then fell by 12.24% to $216.0 million in 2024, then fell by 28.51% to $154.4 million in 2025.
  • Its Invested Capital was $154.4 million in Q3 2025, compared to $174.1 million in Q2 2025 and $195.1 million in Q1 2025.